ReviewJournal of clinical medicine2022
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.Skin health and disease · 2026Review
- Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature.Skin health and disease · 2026Review
- Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly.Frontiers in immunology · 2026Article
- Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.The oncologist · 2025Article
- A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.Dermatology and therapy · 2025Review
- Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab.JAAD case reports · 2025Article
- A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab.Skin health and disease · 2025Article
- Dupilumab as a treatment for bullous pemphigoid in a liver transplant recipient: A case report.SAGE open medical case reports · 2025Article
- Dupilumab in patients with bullous pemphigoid and concomitant atopy.Frontiers in pharmacology · 2025Article
- Article
- Successful Treatment of Mucous Membrane Pemphigoid with Dupilumab: A Case Report.Acta dermato-venereologica · 2024Article
- Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review.Journal of clinical medicine · 2024Review
- Article
- Use of dupilumab for recalcitrant bullous pemphigoid: A case report.SAGE open medical case reports · 2024Article
- Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study.Dermatology (Basel, Switzerland) · 2024Article
- Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.Annals of medicine · 2023Review
- Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.Immunity, inflammation and disease · 2023Article
- Article
- Bullous pemphigoid successfully treated with dupilumab.Anais brasileiros de dermatologiaArticle
- Navigating Bullous Pemphigoid: Consensus Recommendations for Diagnosis and Management-A Canadian Perspective.Journal of cutaneous medicine and surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with BP. Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated patients in 9 papers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.